Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus

J Natl Cancer Inst. 2004 Jun 2;96(11):885-7; author reply 887. doi: 10.1093/jnci/djh171.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adenocarcinoma / economics
  • Adenocarcinoma / prevention & control
  • Adult
  • Aged
  • Anti-Ulcer Agents / administration & dosage
  • Anti-Ulcer Agents / economics
  • Aspirin / administration & dosage*
  • Aspirin / economics*
  • Barrett Esophagus / economics*
  • Barrett Esophagus / mortality
  • Barrett Esophagus / prevention & control*
  • Cost-Benefit Analysis
  • Drug Administration Schedule
  • Drug Costs / statistics & numerical data
  • Drug Therapy, Combination
  • Esophageal Neoplasms / economics*
  • Esophageal Neoplasms / prevention & control*
  • Evidence-Based Medicine
  • Humans
  • Male
  • Middle Aged
  • Omeprazole / administration & dosage
  • Omeprazole / economics
  • Prospective Studies
  • Randomized Controlled Trials as Topic
  • Survival Rate
  • United Kingdom

Substances

  • Anti-Ulcer Agents
  • Omeprazole
  • Aspirin